When administering TKIs as treatment for RCC, the primary therapeutic target is the receptor family of vascular endothelial growth factors (VEGFs), consisting of membrane receptor tyrosine kinases 1, 2, and 3 (VEGFR-1, -2, and -3) [18]. Here, VEGFA is linked to renal cell carcinoma.